Lilly Articles
Generic firms file for IP protection in India
16 June 2008
Liraglutide superior to Byetta: LEAD study
16 June 2008
Amylin/Lilly's Byetta achieves glycemic control
16 June 2008
Lilly submits Cymbalta sNDA for chronic pain
9 June 2008
Alkermes' fiscal-2008 income soars on Reliant
9 June 2008
Alimta boosts survival in certain NSCLC types
9 June 2008
Lilly announces major leadership restructuring
26 May 2008
Japan stock market week to May 19, 2008
26 May 2008
FDA clears Lilly's Strattera in ADHD maintenance
19 May 2008
New GSK CEO makes new appointments
5 May 2008
Lilly signs research deal with Entelos
5 May 2008
US drugmaker gift ban urged by AAMC
5 May 2008
Stock Commentary - New York week to April 21, 2008
28 April 2008
Lilly has good 1Q sales but still disappoints
28 April 2008
US drugmakers opt for disclosure of grants
21 April 2008
EMEA clears histology-based use for Alimta
21 April 2008
Japan stock market week to April 7, 2008
14 April 2008
Lilly launches first Ph III AD drug trial
7 April 2008
Sanofi-Aventis to help market Lilly's Cialis in USA
31 March 2008
Lilly settles Zyprexa Alaska case for $15M
31 March 2008
Pfizer moves to keep market share in Japan
24 March 2008
Lilly licenses gastrin agents from TT
24 March 2008
Lilly grants $4M for MDR-TB program
17 March 2008
Promotional spending on atypical antipsychotice analyzed
17 March 2008
Lilly pulls out of inhaled insulin development
17 March 2008
Zyprexa LAI gets FDA non-approvable letter
10 March 2008
Galapagos' 2007 sales to exceed 64M euros
10 March 2008
Japan stock market week to Feb 25, 2008
3 March 2008
FDA awards priority review for prasugrel
3 March 2008
New histology-based use for Alimta
3 March 2008
CHMP recommends Lilly's Forsteo
3 March 2008
Stock Commentary - New York week to Feb 18, 2008
25 February 2008
Acadia appoints John Kaiser VP of commercial development
18 February 2008
FDA c'tee recommends Zyprexa LAI approval
18 February 2008
FDA advisors declare the agency's "science and mission are at risk"
11 February 2008
Amgen sells Takeda Japanese rights to 13 drugs in a deal that could be worth up to $1.2B
11 February 2008
PsychoGenics expands discovery deal with Lilly
11 February 2008
Amylin's loss for 4th-qtr 2007 worsens 32%
4 February 2008
Lilly's 4th qtr recovers from Zyprexa settlement
4 February 2008
Gastrotech in-licenses Lilly IBS drug
4 February 2008
Glenmark's 3rd-qtr FY '08 profit soars 48%
4 February 2008
UK's NICE gives go ahead on S-P's Remicade and Lilly's Alimta
28 January 2008
US Congress to re-open drug import debate
28 January 2008
Lilly hits back at data suppression claims
28 January 2008
Japan stock market week toJan 14, 2008
21 January 2008
Lilly extends R&D accord with Galapagos
21 January 2008
Lanxess sets up US API site for early testing
21 January 2008
Daiichi Sankyo and Eli Lilly submit NDA to US FDA for prasugrel; to be sold as Effient
14 January 2008
US FDA approves Lilly's once-daily Cialis
14 January 2008
Tokyo stocks to January 7, 2008
14 January 2008
Lilly to invest in Italian insulin production
14 January 2008
German generics see drug majors cut prices
14 January 2008
John Lechleiter to succeed Sidney Taurel as Lilly's CEO
7 January 2008
UK's fraud probe of AZ and GSK deals in Iraq
7 January 2008
China's largest pharmacy chain signs 16 drug firms
24 December 2007
Lilly lowers guidance on MS drug buy
24 December 2007
Eli Lilly gives drug rights to US university
24 December 2007
Headlines 25 years ago this week....
17 December 2007
3rd-qtr global pharmaceutical R&D pipeline report from Fitch
17 December 2007
UK's PMCPA names six firms in violation of Code
17 December 2007
Amylin/ lilly plan Byetta monotherapy filing
17 December 2007
Japan stock market week to Dec 3, 2007
10 December 2007
Raft of pending patent expiries threaten cardiovascular blockbusters
10 December 2007
Additional indication for Lilly's Cymbalta
10 December 2007
Lilly funds Red Cross/Crescent programs
10 December 2007
EAEPC attacks EAASM as "sheer propaganda tool"
3 December 2007
Call for EU review of parallel trade by EAASM
26 November 2007
Lilly/Daiichi Sankyo's prasugrel cuts CV AEs 19% vs Plavix, but side effects raise doubts
21 November 2007
Lilly and JDRF partner on beta cell biomarker identification
19 November 2007
FDA orders GSK to add warning to Avandia
19 November 2007
Actavis' olanzapine launched in Germany
19 November 2007
Japan stock market week to November 5, 2007
12 November 2007
Headlines 25 years ago this week....
12 November 2007
Japan stock market week to Oct 29, 2007
5 November 2007
Lilly licenses Glenmark's TRPV1 blocker portfolio
5 November 2007
Two prasugrel trials suspended on dosage issues
29 October 2007
EMEA: Avandia/Actos benefits outweigh risks
29 October 2007
Amylin's 3rd-qtr net loss narrows to $39.8M
29 October 2007
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
